Pages that link to "Q43029925"

The following pages link to Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine (Q43029925):

Displaying 42 items.

• Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. (Q27472875) (← links)
• Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine Vehicle (Q27473287) (← links)
• Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...] (Q27486582) (← links)
• The way forward in HCV treatment--finding the right path (Q34008483) (← links)
• Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy (Q34008754) (← links)
• Hepatitis C vaccine: supply and demand (Q34011890) (← links)
• Hepatitis C virus core protein: intriguing properties and functional relevance (Q34345314) (← links)
• Recent developments in adjuvants for vaccines against infectious diseases (Q34376294) (← links)
• Lipopeptide vaccines--yesterday, today, and tomorrow (Q34749774) (← links)
• Recent advances in vaccine adjuvants (Q34756188) (← links)
• Will there be a vaccine to prevent HCV infection? (Q34781537) (← links)
• Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. (Q34880294) (← links)
• The challenge of developing a vaccine against hepatitis C virus (Q34979868) (← links)
• Development of a hepatitis C virus vaccine (Q35105726) (← links)
• Hepatitis vaccines: recent advances (Q35143274) (← links)
• ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses (Q35802771) (← links)
• Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators (Q35826747) (← links)
• ISCOM-based vaccines: the second decade. (Q36062124) (← links)
• The evaluation of hepatitis C virus core antigen in immunized BALB/c mice (Q36142757) (← links)
• Prospects for a vaccine against the hepatitis C virus (Q36233831) (← links)
• Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine. (Q36316087) (← links)
• Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon (Q36587760) (← links)
• Microparticle-based technologies for vaccines (Q36602257) (← links)
• Preparation of recombinant vaccines. (Q36944222) (← links)
• Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant (Q37452772) (← links)
• ISCOMs and ISCOMATRIX. (Q37486921) (← links)
• Progress towards a hepatitis C virus vaccine (Q37584338) (← links)
• Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design (Q37792984) (← links)
• Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses (Q37825527) (← links)
• Dendritic cells in hepatitis C infection: can they (help) win the battle? (Q37843841) (← links)
• Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives (Q37945171) (← links)
• Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities (Q37997825) (← links)
• Current progress in development of hepatitis C virus vaccines. (Q38120201) (← links)
• An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model (Q39813695) (← links)
• Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System (Q39860495) (← links)
• Perspectives: towards a peptide-based vaccine against hepatitis C virus. (Q43035611) (← links)
• Cationic microparticles are a potent delivery system for a HCV DNA vaccine (Q45149602) (← links)
• In vivo activity of cationic immune stimulating complexes (PLUSCOMs). (Q46514400) (← links)
• Hepatitis C vaccines (Q57160237) (← links)
• Approaches, Progress, and Challenges to Hepatitis C Vaccine Development (Q59351582) (← links)
• Novel application of trimethyl chitosan as an adjuvant in vaccine delivery (Q59812625) (← links)
• Improvement of human interferon HUIFNalpha2 and HCV core protein expression levels in Escherichia coli but not of HUIFNalpha8 by using the tRNA(AGA/AGG) (Q74707441) (← links)